MedTrace Logo

iNOPulse for COVID-19

NCT04398290 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-08-19

No results posted yet for this study

Summary

This randomized, controlled trial will assess the efficacy and safety of pulsed iNO in subjects with COVID-19 who are hospitalized and require supplemental oxygen.

Conditions

  • COVID-19
  • Hypoxemia
  • Hypoxemic Respiratory Failure

Interventions

DRUG

Inhaled nitric oxide (iNO)

iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour

DRUG

Nitrogen gas

250 mcg/kg ideal body weight (IBW)/hour

DRUG

Oxygen gas

Supplemental oxygen administered via nasal cannula

Sponsors & Collaborators

  • Bellerophon Therapeutics

    collaborator UNKNOWN

  • Roger Alvarez

    lead OTHER

Principal Investigators

  • Roger A Alvarez, D.O. · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-06-01
Completion
2021-07-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04398290 on ClinicalTrials.gov